Obliterative bronchiolitis after lung and heart-lung transplantation

Hermann Reichenspurner, Reda E. Girgis, Robert C. Robbins, John V. Conte, Rajan V. Nair, Vincent Valentine, Gerald J. Berry, Randall E. Morris, James Theodore, Bruce A. Reitz

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Obliterative bronchiolitis (OB) has emerged as the main cause of morbidity and mortality in the long-term follow-up after lung and heart-lung transplantation. The pathogenesis of OB is multifactorial, with acute rejection and cytomegalovirus infection being the main risk factors for the development of OB. The final common pathway of all inciting events seems to be an alloimmune injury, with subsequent release of immunologic medicators and production of growth factors leading to luminal obliteration and fibrous scarring of the small airways. Analyzing the 14 years of experience in 163 patients at Stanford University, we found a current incidence of bronchiolitis obliterans syndrome or histologically proven OB within the first 3 years after lung and heartlung transplantation of 36.3%, with an overall prevalence of 58.1% after heart-lung and 51.4% after lung transplantation. Both pulmonary function indices (forced experiratory flow between 25% and 75% of forced vital capacity and forced expiratory volume in 1 second) and transbronchial biopsies have proven helpful in diagnosing bronchiolitis obliterans syndrome or OB at an early stage. Early diagnosis of OB and improved management have achieved survival rates in patients with OB after 1, 3, 5, and 10 years of 83%, 66%, 46%, and 22%, compared with 86%, 83%, 67%, and 67% in patients without OB. Recently, different experimental models have been developed to investigate the cellular and molecular events leading to OB and to evaluate new treatment strategies for this complication, which current limits the long-term success of heart-lung and lung transplantation.

Original languageEnglish (US)
Pages (from-to)1845-1853
Number of pages9
JournalThe Annals of Thoracic Surgery
Volume60
Issue number6
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Heart-Lung Transplantation
Bronchiolitis
Lung
Lung Transplantation
Bronchiolitis Obliterans
Vital Capacity
Forced Expiratory Volume
Cytomegalovirus Infections
Cicatrix
Early Diagnosis
Intercellular Signaling Peptides and Proteins
Theoretical Models
Survival Rate
Morbidity
Biopsy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine
  • Surgery

Cite this

Reichenspurner, H., Girgis, R. E., Robbins, R. C., Conte, J. V., Nair, R. V., Valentine, V., ... Reitz, B. A. (1995). Obliterative bronchiolitis after lung and heart-lung transplantation. The Annals of Thoracic Surgery, 60(6), 1845-1853. https://doi.org/10.1016/0003-4975(95)00776-8

Obliterative bronchiolitis after lung and heart-lung transplantation. / Reichenspurner, Hermann; Girgis, Reda E.; Robbins, Robert C.; Conte, John V.; Nair, Rajan V.; Valentine, Vincent; Berry, Gerald J.; Morris, Randall E.; Theodore, James; Reitz, Bruce A.

In: The Annals of Thoracic Surgery, Vol. 60, No. 6, 1995, p. 1845-1853.

Research output: Contribution to journalArticle

Reichenspurner, H, Girgis, RE, Robbins, RC, Conte, JV, Nair, RV, Valentine, V, Berry, GJ, Morris, RE, Theodore, J & Reitz, BA 1995, 'Obliterative bronchiolitis after lung and heart-lung transplantation', The Annals of Thoracic Surgery, vol. 60, no. 6, pp. 1845-1853. https://doi.org/10.1016/0003-4975(95)00776-8
Reichenspurner H, Girgis RE, Robbins RC, Conte JV, Nair RV, Valentine V et al. Obliterative bronchiolitis after lung and heart-lung transplantation. The Annals of Thoracic Surgery. 1995;60(6):1845-1853. https://doi.org/10.1016/0003-4975(95)00776-8
Reichenspurner, Hermann ; Girgis, Reda E. ; Robbins, Robert C. ; Conte, John V. ; Nair, Rajan V. ; Valentine, Vincent ; Berry, Gerald J. ; Morris, Randall E. ; Theodore, James ; Reitz, Bruce A. / Obliterative bronchiolitis after lung and heart-lung transplantation. In: The Annals of Thoracic Surgery. 1995 ; Vol. 60, No. 6. pp. 1845-1853.
@article{d347425776ae45ee9209c259abf022ae,
title = "Obliterative bronchiolitis after lung and heart-lung transplantation",
abstract = "Obliterative bronchiolitis (OB) has emerged as the main cause of morbidity and mortality in the long-term follow-up after lung and heart-lung transplantation. The pathogenesis of OB is multifactorial, with acute rejection and cytomegalovirus infection being the main risk factors for the development of OB. The final common pathway of all inciting events seems to be an alloimmune injury, with subsequent release of immunologic medicators and production of growth factors leading to luminal obliteration and fibrous scarring of the small airways. Analyzing the 14 years of experience in 163 patients at Stanford University, we found a current incidence of bronchiolitis obliterans syndrome or histologically proven OB within the first 3 years after lung and heartlung transplantation of 36.3{\%}, with an overall prevalence of 58.1{\%} after heart-lung and 51.4{\%} after lung transplantation. Both pulmonary function indices (forced experiratory flow between 25{\%} and 75{\%} of forced vital capacity and forced expiratory volume in 1 second) and transbronchial biopsies have proven helpful in diagnosing bronchiolitis obliterans syndrome or OB at an early stage. Early diagnosis of OB and improved management have achieved survival rates in patients with OB after 1, 3, 5, and 10 years of 83{\%}, 66{\%}, 46{\%}, and 22{\%}, compared with 86{\%}, 83{\%}, 67{\%}, and 67{\%} in patients without OB. Recently, different experimental models have been developed to investigate the cellular and molecular events leading to OB and to evaluate new treatment strategies for this complication, which current limits the long-term success of heart-lung and lung transplantation.",
author = "Hermann Reichenspurner and Girgis, {Reda E.} and Robbins, {Robert C.} and Conte, {John V.} and Nair, {Rajan V.} and Vincent Valentine and Berry, {Gerald J.} and Morris, {Randall E.} and James Theodore and Reitz, {Bruce A.}",
year = "1995",
doi = "10.1016/0003-4975(95)00776-8",
language = "English (US)",
volume = "60",
pages = "1845--1853",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Obliterative bronchiolitis after lung and heart-lung transplantation

AU - Reichenspurner, Hermann

AU - Girgis, Reda E.

AU - Robbins, Robert C.

AU - Conte, John V.

AU - Nair, Rajan V.

AU - Valentine, Vincent

AU - Berry, Gerald J.

AU - Morris, Randall E.

AU - Theodore, James

AU - Reitz, Bruce A.

PY - 1995

Y1 - 1995

N2 - Obliterative bronchiolitis (OB) has emerged as the main cause of morbidity and mortality in the long-term follow-up after lung and heart-lung transplantation. The pathogenesis of OB is multifactorial, with acute rejection and cytomegalovirus infection being the main risk factors for the development of OB. The final common pathway of all inciting events seems to be an alloimmune injury, with subsequent release of immunologic medicators and production of growth factors leading to luminal obliteration and fibrous scarring of the small airways. Analyzing the 14 years of experience in 163 patients at Stanford University, we found a current incidence of bronchiolitis obliterans syndrome or histologically proven OB within the first 3 years after lung and heartlung transplantation of 36.3%, with an overall prevalence of 58.1% after heart-lung and 51.4% after lung transplantation. Both pulmonary function indices (forced experiratory flow between 25% and 75% of forced vital capacity and forced expiratory volume in 1 second) and transbronchial biopsies have proven helpful in diagnosing bronchiolitis obliterans syndrome or OB at an early stage. Early diagnosis of OB and improved management have achieved survival rates in patients with OB after 1, 3, 5, and 10 years of 83%, 66%, 46%, and 22%, compared with 86%, 83%, 67%, and 67% in patients without OB. Recently, different experimental models have been developed to investigate the cellular and molecular events leading to OB and to evaluate new treatment strategies for this complication, which current limits the long-term success of heart-lung and lung transplantation.

AB - Obliterative bronchiolitis (OB) has emerged as the main cause of morbidity and mortality in the long-term follow-up after lung and heart-lung transplantation. The pathogenesis of OB is multifactorial, with acute rejection and cytomegalovirus infection being the main risk factors for the development of OB. The final common pathway of all inciting events seems to be an alloimmune injury, with subsequent release of immunologic medicators and production of growth factors leading to luminal obliteration and fibrous scarring of the small airways. Analyzing the 14 years of experience in 163 patients at Stanford University, we found a current incidence of bronchiolitis obliterans syndrome or histologically proven OB within the first 3 years after lung and heartlung transplantation of 36.3%, with an overall prevalence of 58.1% after heart-lung and 51.4% after lung transplantation. Both pulmonary function indices (forced experiratory flow between 25% and 75% of forced vital capacity and forced expiratory volume in 1 second) and transbronchial biopsies have proven helpful in diagnosing bronchiolitis obliterans syndrome or OB at an early stage. Early diagnosis of OB and improved management have achieved survival rates in patients with OB after 1, 3, 5, and 10 years of 83%, 66%, 46%, and 22%, compared with 86%, 83%, 67%, and 67% in patients without OB. Recently, different experimental models have been developed to investigate the cellular and molecular events leading to OB and to evaluate new treatment strategies for this complication, which current limits the long-term success of heart-lung and lung transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0029549667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029549667&partnerID=8YFLogxK

U2 - 10.1016/0003-4975(95)00776-8

DO - 10.1016/0003-4975(95)00776-8

M3 - Article

C2 - 8787504

AN - SCOPUS:0029549667

VL - 60

SP - 1845

EP - 1853

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 6

ER -